1Department of Nursing, Keimyung University Dongsan Hospital, Daegu, Korea
2College of Nursing, Keimyung University, Daegu, Korea
© 2026 The Korean Society of Critical Care Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was reported.
FUNDING
None.
ACKNOWLEDGMENTS
The authors thank the nursing staff of the Rapid Response Team at Keimyung University Dongsan Hospital for their dedication to patient safety and the integrity of clinical records.
AUTHOR CONTRIBUTIONS
Conceptualization: GK. Methodology: GK. Formal analysis: SG. Data curation: SG. Writing - original draft: SG, BK. Writing - review & editing: BK, GK. All authors read and agreed to the published version of the manuscript.
The reference group was "no" for categorical variables and ≤0.5 ng/ml for procalcitonin. Hosmer-Lemeshow χ²=5.295 (df=8, P=0.726); Cox & Snell R²=0.213; Nagelkerke R²=0.291. The multivariable model incorporating procalcitonin was estimated by complete-case analysis restricted to the 130 patients with available procalcitonin (no imputation was performed for the remaining patients); the goodness-of-fit and discrimination statistics above refer to this 130-patient subsample, whereas univariate ORs were computed using all available data for each variable.
ICU: intensive care unit; RRT: rapid response team; OR: odds ratio; aOR: adjusted odds ratio; S/F ratio: SpO₂/FiO₂ ratio; SpO₂: peripheral oxygen saturation; FiO₂: fraction of inspired oxygen; DeepCARS: deep learning-based continuous cardiac arrest risk score.
| Variable | All patients (n=549) | ICU group (n=191) | Ward group (n=358) | χ² or t | P-value |
|---|---|---|---|---|---|
| Demographic and baseline characteristics | |||||
| Age (yr) | 70±13 | 68±14 | 71±12 | −2.250 | 0.025 |
| Male sex | 323 (58.8) | 108 (56.5) | 215 (60.1) | 0.643 | 0.426 |
| Admitting department | 7.168 | 0.028 | |||
| Medical | 376 (68.5) | 117 (61.3) | 259 (72.3) | ||
| Surgical | 108 (19.7) | 47 (24.6) | 61 (17.0) | ||
| Other | 65 (11.8) | 27 (14.1) | 38 (10.6) | ||
| Underlying comorbidity | |||||
| Solid tumor | 217 (39.5) | 53 (27.7) | 164 (45.8) | 17.213 | <0.001 |
| Diabetes mellitus | 225 (41.0) | 71 (37.2) | 154 (43.0) | 1.759 | 0.185 |
| Chronic lung disease | 95 (17.3) | 20 (10.5) | 75 (20.9) | 9.557 | 0.002 |
| Cardiovascular disease | 339 (61.7) | 118 (61.8) | 221 (61.7) | <0.001 | 0.991 |
| Hepatobiliary disease | 64 (11.7) | 32 (16.8) | 32 (8.9) | 7.387 | 0.007 |
| Cerebrovascular disease | 139 (25.3) | 50 (26.2) | 89 (24.9) | 0.114 | 0.735 |
| Chronic kidney disease | 109 (19.9) | 43 (22.5) | 66 (18.4) | 1.301 | 0.254 |
| Solid organ transplantation | 20 (3.6) | 12 (6.3) | 8 (2.2) | 5.814 | 0.016 |
| Clinical characteristics at RRT activation | |||||
| Oxygen therapy | 464 (84.5) | 177 (92.7) | 287 (80.2) | 14.878 | <0.001 |
| DeepCARS score | 90.44±11.02 | 89.14±12.40 | 91.12±10.19 | −1.990 | 0.047 |
| Vital sign | |||||
| MAP (mm Hg) | 75.02±32.30 | 65.52±39.82 | 80.09±26.14 | - | <0.001 |
| HR (bpm) | 108.78±28.69 | 106.56±28.59 | 109.78±28.72 | - | 0.246 |
| SpO₂ (%) | 92.57±10.56 | 90.78±11.49 | 93.37±10.02 | - | 0.016 |
| Laboratory parameter | |||||
| S/F ratio | 227.83±142.60 | 167.05±130.15 | 260.26±138.40 | - | <0.001 |
| pH | 7.35±0.36 | 7.33±0.16 | 7.37±0.44 | - | 0.281 |
| HCO₃⁻ (mEq/L) | 22.93±8.03 | 22.26±9.18 | 23.33±7.22 | - | 0.151 |
| Lactate (mmol/L) | 3.37±3.37 | 4.02±3.90 | 2.98±2.95 | - | 0.002 |
| Hemoglobin (g/dl) | 10.58±7.34 | 11.26±12.01 | 10.21±2.20 | - | 0.234 |
| Platelet (×10³/μl) | 188.28±125.13 | 180.86±114.80 | 192.31±130.38 | - | 0.309 |
| NLR | 15.44±19.65 | 14.28±20.60 | 16.06±19.12 | - | 0.316 |
| Potassium (mmol/L) | 4.23±0.93 | 4.23±0.99 | 4.22±0.90 | - | 0.924 |
| Creatinine (mg/dl) | 1.79±1.94 | 1.96±2.09 | 1.70±1.86 | - | 0.134 |
| CRP (mg/dl) | 10.72±9.88 | 9.76±8.58 | 11.26±10.52 | - | 0.108 |
| Procalcitonin (ng/ml)a) | 5.946 | 0.015 | |||
| ≤0.5 | 64 (49.2) | 16 (34.8) | 48 (57.1) | ||
| >0.5 | 66 (50.8) | 30 (65.2) | 36 (42.9) | ||
| Outcome | |||||
| 28-Day mortality | 152 (27.7) | 53 (27.7) | 99 (27.7) | 0.006 | 0.937 |
| In-hospital mortality | 232 (42.3) | 88 (46.1) | 144 (40.2) | 1.960 | 0.162 |
Values are presented as mean±standard deviation or number (%).
RRT: rapid response team; ICU: intensive care unit; DeepCARS: deep learning-based continuous cardiac arrest risk score; MAP: mean arterial pressure; HR: heart rate; SpO₂: peripheral oxygen saturation; S/F ratio: SpO₂/FiO₂ ratio; FiO₂: fraction of inspired oxygen; HCO₃⁻: bicarbonate; NLR: neutrophil-to-lymphocyte ratio; CRP: C-reactive protein.
a)Procalcitonin available in 130 patients.
The reference group for categorical variables was "no." Hosmer-Lemeshow χ²=9.044 (df=8, P=0.339); Cox & Snell R²=0.282; Nagelkerke R²=0.398.
RRT: rapid response team; OR: odds ratio; aOR: adjusted odds ratio; S/F ratio: SpO₂/FiO₂ ratio; SpO₂: peripheral oxygen saturation; FiO₂: fraction of inspired oxygen; DeepCARS: deep learning-based continuous cardiac arrest risk score; ICU: intensive care unit.
The reference group for categorical variables was "no." Hosmer-Lemeshow χ²=8.966 (df=8, P=0.345); Cox & Snell R²=0.300; Nagelkerke R²=0.400. The univariate-to-multivariable reversal of the chronic kidney disease estimate (OR, 0.713 → aOR, 5.100) reflects negative confounding (suppression) by solid tumor, the strongest in-hospital mortality predictor (aOR, 5.342), with which chronic kidney disease was inversely associated in this cohort. Multicollinearity diagnostics for the final model confirmed all variance inflation factors below the conventional threshold of 10 and all tolerance values >0.5, indicating that the reversal is attributable to suppression rather than collinearity.
RRT: rapid response team; OR: odds ratio; aOR: adjusted odds ratio; S/F ratio: SpO₂/FiO₂ ratio; SpO₂: peripheral oxygen saturation; FiO₂: fraction of inspired oxygen; DeepCARS: deep learning-based continuous cardiac arrest risk score; CRP: C-reactive protein; ICU: intensive care unit.
| Variable | Univariate OR (95% CI) | P-value | Multivariable aOR (95% CI) | P-value |
|---|---|---|---|---|
| Solid tumor | 0.438 (0.299–0.641) | <0.001 | 0.142 (0.055–0.371) | <0.001 |
| Oxygen therapy | 3.099 (1.696–5.664) | <0.001 | - | - |
| S/F ratio | 0.995 (0.993–0.996) | <0.001 | 0.998 (0.995–1.001) | 0.116 |
| Lactate (mmol/L) | 1.094 (1.035–1.156) | 0.001 | - | - |
| Solid organ transplantation | 2.958 (1.188–7.367) | 0.020 | - | - |
| Procalcitonin >0.5 ng/ml | 2.500 (1.187–5.266) | 0.016 | 2.833 (1.169–6.866) | 0.021 |
| Age (yr) | 0.985 (0.971–0.998) | 0.024 | - | - |
| Hepatobiliary disease | 1.926 (1.139–3.258) | 0.015 | - | - |
| Chronic lung disease | 0.445 (0.263–0.756) | 0.003 | - | - |
| Hemoglobin (g/dl) | 1.022 (0.989–1.056) | 0.201 | 0.808 (0.659–0.991) | 0.040 |
| DeepCARS score | 0.984 (0.969–1.000) | 0.046 | - | - |
| Variable | All patients (n=549) | ICU group (n=191) | Ward group (n=358) | χ² or t | P-value |
|---|---|---|---|---|---|
| Demographic and baseline characteristics | |||||
| Age (yr) | 70±13 | 68±14 | 71±12 | −2.250 | 0.025 |
| Male sex | 323 (58.8) | 108 (56.5) | 215 (60.1) | 0.643 | 0.426 |
| Admitting department | 7.168 | 0.028 | |||
| Medical | 376 (68.5) | 117 (61.3) | 259 (72.3) | ||
| Surgical | 108 (19.7) | 47 (24.6) | 61 (17.0) | ||
| Other | 65 (11.8) | 27 (14.1) | 38 (10.6) | ||
| Underlying comorbidity | |||||
| Solid tumor | 217 (39.5) | 53 (27.7) | 164 (45.8) | 17.213 | <0.001 |
| Diabetes mellitus | 225 (41.0) | 71 (37.2) | 154 (43.0) | 1.759 | 0.185 |
| Chronic lung disease | 95 (17.3) | 20 (10.5) | 75 (20.9) | 9.557 | 0.002 |
| Cardiovascular disease | 339 (61.7) | 118 (61.8) | 221 (61.7) | <0.001 | 0.991 |
| Hepatobiliary disease | 64 (11.7) | 32 (16.8) | 32 (8.9) | 7.387 | 0.007 |
| Cerebrovascular disease | 139 (25.3) | 50 (26.2) | 89 (24.9) | 0.114 | 0.735 |
| Chronic kidney disease | 109 (19.9) | 43 (22.5) | 66 (18.4) | 1.301 | 0.254 |
| Solid organ transplantation | 20 (3.6) | 12 (6.3) | 8 (2.2) | 5.814 | 0.016 |
| Clinical characteristics at RRT activation | |||||
| Oxygen therapy | 464 (84.5) | 177 (92.7) | 287 (80.2) | 14.878 | <0.001 |
| DeepCARS score | 90.44±11.02 | 89.14±12.40 | 91.12±10.19 | −1.990 | 0.047 |
| Vital sign | |||||
| MAP (mm Hg) | 75.02±32.30 | 65.52±39.82 | 80.09±26.14 | - | <0.001 |
| HR (bpm) | 108.78±28.69 | 106.56±28.59 | 109.78±28.72 | - | 0.246 |
| SpO₂ (%) | 92.57±10.56 | 90.78±11.49 | 93.37±10.02 | - | 0.016 |
| Laboratory parameter | |||||
| S/F ratio | 227.83±142.60 | 167.05±130.15 | 260.26±138.40 | - | <0.001 |
| pH | 7.35±0.36 | 7.33±0.16 | 7.37±0.44 | - | 0.281 |
| HCO₃⁻ (mEq/L) | 22.93±8.03 | 22.26±9.18 | 23.33±7.22 | - | 0.151 |
| Lactate (mmol/L) | 3.37±3.37 | 4.02±3.90 | 2.98±2.95 | - | 0.002 |
| Hemoglobin (g/dl) | 10.58±7.34 | 11.26±12.01 | 10.21±2.20 | - | 0.234 |
| Platelet (×10³/μl) | 188.28±125.13 | 180.86±114.80 | 192.31±130.38 | - | 0.309 |
| NLR | 15.44±19.65 | 14.28±20.60 | 16.06±19.12 | - | 0.316 |
| Potassium (mmol/L) | 4.23±0.93 | 4.23±0.99 | 4.22±0.90 | - | 0.924 |
| Creatinine (mg/dl) | 1.79±1.94 | 1.96±2.09 | 1.70±1.86 | - | 0.134 |
| CRP (mg/dl) | 10.72±9.88 | 9.76±8.58 | 11.26±10.52 | - | 0.108 |
| Procalcitonin (ng/ml) |
5.946 | 0.015 | |||
| ≤0.5 | 64 (49.2) | 16 (34.8) | 48 (57.1) | ||
| >0.5 | 66 (50.8) | 30 (65.2) | 36 (42.9) | ||
| Outcome | |||||
| 28-Day mortality | 152 (27.7) | 53 (27.7) | 99 (27.7) | 0.006 | 0.937 |
| In-hospital mortality | 232 (42.3) | 88 (46.1) | 144 (40.2) | 1.960 | 0.162 |
| Variable | Univariate OR (95% CI) | P-value | Multivariable aOR (95% CI) | P-value |
|---|---|---|---|---|
| S/F ratio | 0.996 (0.994–0.997) | <0.001 | 0.993 (0.989–0.997) | 0.001 |
| Lactate (mmol/L) | 1.198 (1.125–1.275) | <0.001 | 1.265 (1.053–1.519) | 0.012 |
| Potassium (mmol/L) | 1.253 (1.030–1.526) | 0.024 | 1.972 (1.034–3.760) | 0.039 |
| Platelet (×10³/μl) | 0.999 (0.997–1.001) | 0.204 | 0.995 (0.991–0.999) | 0.012 |
| Oxygen therapy | 3.307 (1.661–6.586) | 0.001 | - | - |
| Solid tumor | 1.667 (1.142–2.433) | 0.008 | - | - |
| Cardiovascular disease | 0.549 (0.376–0.803) | 0.002 | - | - |
| DeepCARS score | 1.016 (0.997–1.036) | 0.108 | 1.062 (0.990–1.139) | 0.095 |
| ICU admission | 1.046 (0.707–1.547) | 0.823 | - | - |
| Variable | Univariate OR (95% CI) | P-value | Multivariable aOR (95% CI) | P-value |
|---|---|---|---|---|
| Solid tumor | 1.761 (1.244–2.493) | 0.001 | 5.342 (1.900–15.019) | 0.001 |
| Chronic kidney disease | 0.713 (0.462–1.101) | 0.127 | 5.100 (1.257–20.700) | 0.023 |
| S/F ratio | 0.996 (0.995–0.997) | <0.001 | 0.996 (0.993–0.999) | 0.010 |
| Lactate (mmol/L) | 1.182 (1.106–1.263) | <0.001 | 1.211 (1.018–1.440) | 0.031 |
| Potassium (mmol/L) | 1.163 (0.967–1.398) | 0.109 | 2.190 (1.096–4.376) | 0.026 |
| DeepCARS score | 1.025 (1.007–1.043) | 0.007 | 1.057 (1.001–1.117) | 0.048 |
| Oxygen therapy | 3.454 (1.969–6.058) | <0.001 | - | - |
| pH | 0.051 (0.013–0.196) | <0.001 | - | - |
| CRP (mg/dl) | 1.023 (1.004–1.041) | 0.017 | 1.056 (0.995–1.121) | 0.072 |
| ICU admission | 1.312 (0.920–1.870) | 0.133 | - | - |
The reference group was "no" for categorical variables and ≤0.5 ng/ml for procalcitonin. Hosmer-Lemeshow χ²=5.295 (df=8, P=0.726); Cox & Snell R²=0.213; Nagelkerke R²=0.291. The multivariable model incorporating procalcitonin was estimated by complete-case analysis restricted to the 130 patients with available procalcitonin (no imputation was performed for the remaining patients); the goodness-of-fit and discrimination statistics above refer to this 130-patient subsample, whereas univariate ORs were computed using all available data for each variable. ICU: intensive care unit; RRT: rapid response team; OR: odds ratio; aOR: adjusted odds ratio; S/F ratio: SpO₂/FiO₂ ratio; SpO₂: peripheral oxygen saturation; FiO₂: fraction of inspired oxygen; DeepCARS: deep learning-based continuous cardiac arrest risk score.
Values are presented as mean±standard deviation or number (%). RRT: rapid response team; ICU: intensive care unit; DeepCARS: deep learning-based continuous cardiac arrest risk score; MAP: mean arterial pressure; HR: heart rate; SpO₂: peripheral oxygen saturation; S/F ratio: SpO₂/FiO₂ ratio; FiO₂: fraction of inspired oxygen; HCO₃⁻: bicarbonate; NLR: neutrophil-to-lymphocyte ratio; CRP: C-reactive protein. Procalcitonin available in 130 patients.
The reference group for categorical variables was "no." Hosmer-Lemeshow χ²=9.044 (df=8, P=0.339); Cox & Snell R²=0.282; Nagelkerke R²=0.398. RRT: rapid response team; OR: odds ratio; aOR: adjusted odds ratio; S/F ratio: SpO₂/FiO₂ ratio; SpO₂: peripheral oxygen saturation; FiO₂: fraction of inspired oxygen; DeepCARS: deep learning-based continuous cardiac arrest risk score; ICU: intensive care unit.
The reference group for categorical variables was "no." Hosmer-Lemeshow χ²=8.966 (df=8, P=0.345); Cox & Snell R²=0.300; Nagelkerke R²=0.400. The univariate-to-multivariable reversal of the chronic kidney disease estimate (OR, 0.713 → aOR, 5.100) reflects negative confounding (suppression) by solid tumor, the strongest in-hospital mortality predictor (aOR, 5.342), with which chronic kidney disease was inversely associated in this cohort. Multicollinearity diagnostics for the final model confirmed all variance inflation factors below the conventional threshold of 10 and all tolerance values >0.5, indicating that the reversal is attributable to suppression rather than collinearity. RRT: rapid response team; OR: odds ratio; aOR: adjusted odds ratio; S/F ratio: SpO₂/FiO₂ ratio; SpO₂: peripheral oxygen saturation; FiO₂: fraction of inspired oxygen; DeepCARS: deep learning-based continuous cardiac arrest risk score; CRP: C-reactive protein; ICU: intensive care unit.